AgeX Therapeutics Inc. (AGE)’s Financial Results Comparing With Amarin Corporation plc (NASDAQ:AMRN)

AgeX Therapeutics Inc. (NYSEAMERICAN:AGE) and Amarin Corporation plc (NASDAQ:AMRN) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AgeX Therapeutics Inc. 1.40M 129.66 7.50M -0.16 0.00
Amarin Corporation plc 258.57M 21.46 116.78M -0.34 0.00

Demonstrates AgeX Therapeutics Inc. and Amarin Corporation plc earnings per share (EPS), top-line revenue and valuation.


Table 2 shows us AgeX Therapeutics Inc. and Amarin Corporation plc’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
AgeX Therapeutics Inc. -535.71% 0% 0%
Amarin Corporation plc -45.16% 827.8% -45.9%


AgeX Therapeutics Inc.’s Current Ratio and Quick Ratio are 6.5 and 6.5 respectively. The Current Ratio and Quick Ratio of its competitor Amarin Corporation plc are 2.4 and 2 respectively. AgeX Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to Amarin Corporation plc.

Analyst Recommendations

The table delivered features the ratings and recommendations for AgeX Therapeutics Inc. and Amarin Corporation plc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
AgeX Therapeutics Inc. 0 0 0 0.00
Amarin Corporation plc 0 0 4 3.00

Meanwhile, Amarin Corporation plc’s consensus price target is $35.75, while its potential upside is 113.05%.

Institutional & Insider Ownership

AgeX Therapeutics Inc. and Amarin Corporation plc has shares owned by institutional investors as follows: 17.3% and 49.1%. AgeX Therapeutics Inc.’s share owned by insiders are 45.9%. Comparatively, Amarin Corporation plc has 0.9% of it’s share owned by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
AgeX Therapeutics Inc. -14.43% 7.24% 0% 0% 0% 38.8%
Amarin Corporation plc 9.7% 22.8% 24.22% 567.39% 537.69% 57.9%

For the past year AgeX Therapeutics Inc. was less bullish than Amarin Corporation plc.


Amarin Corporation plc beats on 6 of the 11 factors AgeX Therapeutics Inc.

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The companyÂ’s lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its product principally to wholesalers and specialty pharmacy providers. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.